BACKGROUND: One third of patients with stage T1 urothelial carcinoma (UC) progress to muscle-invasive disease requiring radical surgery. Thus, reliable tools are needed for risk stratification of stage T1 UC. OBJECTIVE: To investigate the extent to which stratification of stage T1 tumours into previously described molecular pathologic UC subtypes can provide improved information on tumour progression. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort of 167 primary stage T1 UCs was characterised by immunohistochemistry and classified into the molecular subtypes urobasal (Uro, 32%), genomically unstable (GU, 58%), and squamous-cell-carcinoma-like (SCCL, 10%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival using univariate and multivariate models. RESULTS AND LIMITATIONS: Subtype classification was validated using nine additional markers with known subtype-specific expression. Analysis of mRNA expression of progression biomarkers revealed a strong association with molecular subtype. Kaplan-Meier analyses showed that the risk of progression was low for Uro tumours and high for GU/SCCL tumours. High progression risk scores were found only for GU/SCCL tumours. Clinical risk factors such as multifocality, concomitant carcinoma in situ, invasion depth, lymphovascular invasion, and high CD3(+) lymphocyte infiltration were observed almost exclusively in GU/SCCL cases. CONCLUSIONS: Molecular subtypes Uro, GU, and SCCL were identified in an independent population-based cohort of stage T1 UCs. Biomarkers and clinical risk factors for progression were associated with molecular subtype. Rapidly progressing T1 tumours were of subtype GU or SCCL and had either a high progression risk score or an elevated CD3(+) cell count. PATIENT SUMMARY: We show that classification of stage T1 urothelial carcinoma into molecular subtypes can improve the identification of patients with progressing tumours.
BACKGROUND: One third of patients with stage T1 urothelial carcinoma (UC) progress to muscle-invasive disease requiring radical surgery. Thus, reliable tools are needed for risk stratification of stage T1 UC. OBJECTIVE: To investigate the extent to which stratification of stage T1 tumours into previously described molecular pathologic UC subtypes can provide improved information on tumour progression. DESIGN, SETTING, AND PARTICIPANTS: A population-based cohort of 167 primary stage T1 UCs was characterised by immunohistochemistry and classified into the molecular subtypes urobasal (Uro, 32%), genomically unstable (GU, 58%), and squamous-cell-carcinoma-like (SCCL, 10%). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Progression-free survival using univariate and multivariate models. RESULTS AND LIMITATIONS: Subtype classification was validated using nine additional markers with known subtype-specific expression. Analysis of mRNA expression of progression biomarkers revealed a strong association with molecular subtype. Kaplan-Meier analyses showed that the risk of progression was low for Uro tumours and high for GU/SCCL tumours. High progression risk scores were found only for GU/SCCL tumours. Clinical risk factors such as multifocality, concomitant carcinoma in situ, invasion depth, lymphovascular invasion, and high CD3(+) lymphocyte infiltration were observed almost exclusively in GU/SCCL cases. CONCLUSIONS: Molecular subtypes Uro, GU, and SCCL were identified in an independent population-based cohort of stage T1 UCs. Biomarkers and clinical risk factors for progression were associated with molecular subtype. Rapidly progressing T1 tumours were of subtype GU or SCCL and had either a high progression risk score or an elevated CD3(+) cell count. PATIENT SUMMARY: We show that classification of stage T1 urothelial carcinoma into molecular subtypes can improve the identification of patients with progressing tumours.
Authors: Zachary E Hoggarth; Danyelle B Osowski; Andrea Slusser-Nore; Swojani Shrestha; Prakash Pathak; Theoren Solseng; Scott H Garrett; Divyen H Patel; Evan Savage; Donald A Sens; Seema Somji Journal: Toxicol Appl Pharmacol Date: 2019-04-29 Impact factor: 4.219
Authors: Laura-Maria Krabbe; Vitaly Margulis; Andres Jan Schrader; Shahrokh F Shariat; Kilian M Gust; Martin Boegemann Journal: World J Urol Date: 2018-06-08 Impact factor: 4.226
Authors: Woonyoung Choi; Andrea Ochoa; David J McConkey; Mattias Aine; Mattias Höglund; William Y Kim; Francisco X Real; Anne E Kiltie; Ian Milsom; Lars Dyrskjøt; Seth P Lerner Journal: Eur Urol Date: 2017-03-30 Impact factor: 20.096
Authors: Jeremy Yuen-Chun Teoh; Ashish M Kamat; Peter C Black; Petros Grivas; Shahrokh F Shariat; Marek Babjuk Journal: Nat Rev Urol Date: 2022-03-31 Impact factor: 16.430
Authors: Joaquim Bellmunt; Jaegil Kim; Brendan Reardon; Júlia Perera-Bel; Anna Orsola; Alejo Rodriguez-Vida; Stephanie A Wankowicz; Michaela Bowden; Justine A Barletta; Juan Morote; Inés de Torres; Nuria Juanpere; Josep Lloreta-Trull; Silvia Hernandez; Kent W Mouw; Mary-Ellen Taplin; Paloma Cejas; Henry W Long; Eliezer M Van Allen; Gad Getz; David J Kwiatkowski Journal: Cancer Res Date: 2020-08-31 Impact factor: 13.312